PPI 会造成依赖：这种药物"制造了它声称要治疗的疾病"，使得为一时不适而进行的短期治疗变成慢性依赖，让人"停不下来"。
原始表述
لكنّ المفتاح الذي يفسّر الإدمان الذي يصفه د. ضياء هو دراسة ريمر (Gastroenterology 2009): 120 متطوعاً صحيحاً تماماً، أُعطوا إيزوميبرازول 40 ملغ ثمانية أسابيع. بعد التوقف، 44% منهم ظهرت لديهم حرقة وارتداد لأول مرة في حياتهم، مقابل 15% للغفل. الدواء يخلق المرض الذي يدّعي علاجه. هذا هو الفخّ الذي يحذّر منه: ابدأ نكسيم لشكوى عابرة، فلا تستطيع التوقف.
非原话——为转述. 译文由本项目提供；以阿拉伯语原文为准。
译文
PPI 会造成依赖：这种药物"制造了它声称要治疗的疾病"，使得为一时不适而进行的短期治疗变成慢性依赖，让人"停不下来"。
出处
- 来源状态
- 档案网站编辑
- 归属
- Archive editors (eltayebat.com); not verified as Elawady's own words
- 出处
- https://eltayebat.com/rule/acid-blockers/
- 归属的不确定性
- Written by the archive operators; study selection is the archive's, not necessarily Elawady's.
- 所声称的机制
Rebound acid hypersecretion.
- 所声称的健康影响
Lifelong dependence.
- 涉及人群
PPI users.
- Elawady 设定的地域限制
none found
来源版本存在差异
حمض المعدة ليس عدوّاً يجب قمعه، بل أداة أساسية للهضم وقتل الميكروبات وامتصاص الحديد وفيتامين ب12 والكالسيوم والمغنيزيوم. تثبيطه لفترات طويلة بـ PPIs (أوميبرازول، نكسيم، كونترلوك) أو مثبطات H2 ينقلب على الجسم: مرض كلوي مزمن، فرط نمو بكتيري، عدوى مطثية عسيرة، التهاب رئوي، نقص B12 والمغنيزيوم، كسور ورك، تغيّر الميكروبيوم، وزيادة الوفيات. والأخطر أنّ الجسم يدمن الدواء عبر فرط الإفراز الارتدادي بعد الإيقاف، فيتحوّل الاستخدام القصير إلى اعتماد مزمن.
- 来源状态
- 档案网站编辑
- 归属
- Archive editors (eltayebat.com)
- 出处
- https://eltayebat.com/rule/acid-blockers/
科学评估
基本错误 – 该说法的主要部分没有证据支持，或被严重夸大。
证据确定性: 中 – 进一步研究仍可能影响该评估。
1. 说法是什么？
PPIs create an inescapable dependence.
2. 哪些内容可证实是正确的？
Rebound symptoms can make stopping harder and may contribute to unnecessary long-term use (a hypothesis stated in Lødrup 2013).
3. 哪些内容是错误或夸大的？
'Cannot stop' is not supported: guidelines (Farrell 2017; AGA 2022) describe successful dose reduction, on-demand use and discontinuation in suitable patients, by tapering or abrupt stop. 'Addiction' is not the right concept: there is no craving or compulsive use.
4. 哪些内容仍不明确？
How often rebound is the main reason for long-term use in practice is not known.
5. 哪些研究支持该说法？
A-PPI-14 and Niklasson 2010 (I-PPI-104): rebound symptoms after withdrawal (mechanism only); Namikawa 2024 (I-PPI-105): rebound may lead patients to restart PPIs unnecessarily; Cochrane 2017 (I-PPI-103): more symptoms with on-demand use in mild GERD.
6. 哪些研究与该说法相矛盾？
Koggel 2026 RCT (I-PPI-106): 86% vs 64% discontinued within 2 months; Cochrane 2017 (I-PPI-103): pill burden -3.79 pills/week; Farrell 2017 (I-PPI-05), AGA 2022 (I-PPI-04), Lodrup 2013 (I-PPI-06).
7. 对德国和欧洲而言情况如何？
PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.
8. 关于埃及的已知情况是什么？
Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.
9. 合理的实际结论是什么？
想停用 PPI 的人应在医生指导下进行，并预计可能会有几周的反跳；患有 Barrett 食管、重度食管炎或有出血风险的人，未经专科医生建议不应停药。
评估详情
- 证据确定性的依据
Rebound is real but transient (two placebo-controlled RCTs: A-PPI-14, I-PPI-104; symptoms gone by week 3 in I-PPI-104). A 2026 randomised trial in outpatients without a chronic indication found that 64% (brochure) to 86% (app) had stopped PPIs after 2 months (I-PPI-106), and a Cochrane review found that deprescribing reduces pill burden, although on-demand use increases symptoms in some people with mild GERD (I-PPI-103). Guidelines describe tapering or abrupt discontinuation (I-PPI-04, I-PPI-05). No evidence of pharmacological addiction was found.
- 来源质量
Archive editorial extrapolation from one volunteer RCT.
- 地区可推广性
High.
- 个体例外情况
Patients with ongoing reflux disease may genuinely need long-term therapy; this is not dependence.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
过度解读 – 确有真实的发现，但该说法从中引申出的结论超出了数据所能支持的范围（例如把关联当作因果、把动物数据套用到人身上、把小效应说成大效应）。
研究问题: Do PPIs create dependence so that a short course turns into chronic use and one 'cannot stop'?
研究问题详解 (PICO)
- 人群
- Long-term PPI users without a continuing indication
- 干预或暴露
- Deprescribing (stop, taper, on-demand)
- 对照
- Continued use
- 地域范围
- universal pharmacology
- 结局指标
- Successful discontinuation
- Symptom relapse
- Adverse withdrawal events
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Are acid blockers addictive?
Expert review: rebound may lead patients to restart PPIs because symptoms are mistaken for relapse.
- 实际结果
- 40-50% symptomatic after withdrawal in volunteers
- 方法学质量
- low (narrative review)
- 相关性
- direct for the mechanism of unnecessary continuation
- 局限
- Narrative
Cutting down acid blockers: fewer pills, more symptoms for some
Boghossian TA et al.. Cochrane Database Syst Rev 2017 · PMID 28301676 · DOI 10.1002/14651858.CD011969.pub2 系统综述已核查摘要新增Cochrane: on-demand deprescribing increases lack of symptom control.
- 实际结果
- RR 1.71 (1.31-2.21), low-quality
- 方法学质量
- high (Cochrane) / low-quality evidence
- 相关性
- direct
- 局限
- Mild GERD only
哪些证据不支持该说法？
Most people could stop unnecessary acid blockers
Koggel LM et al.. United European Gastroenterol J 2026 · PMID 42894466 · DOI 10.1002/ueg2.70297 随机对照试验已核查全文新增RCT: among outpatients without indication, most stopped PPIs within 2 months.
- 实际结果
- 86% (app) and 64% (brochure) discontinued; RR 1.34 (1.11-1.61)
- 方法学质量
- moderate (open-label RCT, full text)
- 相关性
- direct
- 局限
- 2-month follow-up; self-report
Cutting down acid blockers: fewer pills, more symptoms for some
Boghossian TA et al.. Cochrane Database Syst Rev 2017 · PMID 28301676 · DOI 10.1002/14651858.CD011969.pub2 系统综述已核查摘要新增Cochrane: deprescribing reduced pill burden.
- 实际结果
- MD -3.79 pills/week (moderate quality)
- 方法学质量
- high
- 相关性
- direct
- 局限
- Mild GERD
How to stop PPIs safely (AGA 2022)
Targownik LE et al.. Gastroenterology 2022 · PMID 35183361 · DOI 10.1053/j.gastro.2021.12.247 指南 / 立场声明已核查摘要AGA 2022: tapering or abrupt discontinuation both possible; warn about transient rebound.
- 实际结果
- BPA 8-9
- 方法学质量
- guideline
- 相关性
- direct
- 局限
- Expert review
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Rebound can make stopping uncomfortable and may sustain unnecessary use, but most people without an indication can stop; there is no addiction in the pharmacological sense.
为什么有些研究权重更大
RCT data on discontinuation and Cochrane evidence outweigh narrative concerns.
因果关系是否已确立？ 不适用 Dependence in the sense of being unable to stop is contradicted by trial data.
仍存在的不确定性
Long-term relapse after discontinuation.
合理的结论
Overstated.
为什么研究结果看起来互相矛盾？
Cochrane (more symptoms with on-demand use) vs Koggel (most can stop) answer different questions: symptom control in GERD patients vs discontinuation in people without indication.
这是否取决于国家？
- 一般生物学效应
- Pharmacology of PPIs is the same in Egypt and Europe.
- 饮食习惯
- Not decisive.
- 食品原产地
- Not relevant.
- 污染物
- Not relevant (except ranitidine NDMA impurities, C-PPI-08).
- 本国生产条件
- Generic products are used in both regions; no evidence of different pharmacological effects.
- 法律规则
- PPIs are partly available without prescription in Egypt and (small packs, short-term) in the EU; prescribing practices differ.
- 实际监测数据
- No Egyptian outcome data identified; one Egypt/Iraq pharmacist survey (I-PPI-120).
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Recalculated RR and Wilson CIs – RR 1.34 (1.12-1.61) matches; brochure arm 64% (53%-73%) 已重新计算
- Log-symmetry – RR 1.71 (1.31-2.21) consistent 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Ability to discontinue PPIs without indication
- 起始等级
- 高（随机试验）
- 降级理由
- risk of bias (open-label, self-report)
- imprecision
- 结果
- 中
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- AGA (American Gastroenterological Association): AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review (Targownik LE et al., Gastroenterology 2022; I-PPI-04) (2022) · 原始文献
Best Practice Advice read verbatim in the PubMed record: regular review and documentation of the indication (BPA 1); trial of de-prescribing for all without a definitive indication (BPA 2); complicated GERD (severe erosive oesophagitis, oesophageal ulcer, peptic stricture) generally not for discontinuation (BPA 4); Barrett's oesophagus, eosinophilic oesophagitis, idiopathic pulmonary fibrosis generally not for de-prescribing (BPA 5); assess upper GI bleeding risk first and do not de-prescribe in high-risk patients (BPA 6-7); warn about transient rebound symptoms (BPA 8); tapering or abrupt stop both possible (BPA 9); decide on indication, not on fear of PPI-associated adverse events (BPA 10). The publisher page could not be fetched (HTTP 403). - ACG (American College of Gastroenterology): ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease (Katz PO et al. 2022; I-PPI-10) (2022) · 原始文献
Full text read: weight loss recommended for overweight/obese patients (strong, moderate evidence); avoid meals within 2-3 h of bedtime, avoid tobacco, avoid 'trigger foods', elevate head of bed for nocturnal symptoms (conditional, low evidence); Table 3 rates 'avoid carbonated beverages' as moderate evidence and recommendable; PPIs over H2RAs for healing erosive oesophagitis (strong, high evidence); attempt to discontinue PPIs in patients without erosive oesophagitis or Barrett's whose symptoms resolved (conditional, low); maintenance PPI indefinitely or surgery for LA grade C/D oesophagitis (strong, moderate); endoscopy first for dysphagia or alarm symptoms (weight loss, GI bleeding); rebound shown in healthy controls but strong evidence for symptom increase after abrupt withdrawal in patients is lacking.
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | TITLE:(dyspeptic OR "acid-related" OR rebound OR "acid hypersecretion") AND TITLE:(discontinuation OR withdrawal OR cessation OR stopping) AND (proton OR esomeprazole OR pantoprazole OR omeprazole OR lansoprazole) | 双向 | 15 | |
| Europe PMC | 2026年10月26日 | TITLE:deprescribing AND TITLE:"proton pump inhibitor" AND (cochrane OR "systematic review") | 双向 | 3 | |
| PubMed (E-utilities esearch) | 2026年10月26日 | (proton pump inhibitors[mh]) AND (deprescriptions[mh] OR discontinu*[ti]) AND (randomized controlled trial[pt] OR systematic review[pt]) | 双向 | 17 | |
| PubMed efetch (record of PMID 35183361) | 2026年10月26日 | efetch id=35183361 (AGA 2022 de-prescribing BPA statements); publisher page attempted via WebFetch returned HTTP 403 | 指南 | 1 | |
| Web (curl/WebFetch of guideline page) | 2026年10月26日 | https://pmc.ncbi.nlm.nih.gov/articles/PMC8754510/ (ACG 2022 GERD guideline full text; Europe PMC fullTextXML returned HTTP 500) | 指南 | 1 |
待解决的问题
Sustained discontinuation beyond 2 months.
核查深度如何？
8 项相关研究：1 项核查了全文（其中 0 项进行了结构化偏倚风险评估），7 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 基本错误 (低)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 评定结论已更改: 基本错误 (低) → 基本错误 (中)
Certainty raised: a randomised discontinuation trial (2026) and the Cochrane review now provide direct evidence that most people can stop; previously the judgement relied on guidelines.
新来源: I-PPI-103 I-PPI-104 I-PPI-105 I-PPI-106
通俗解释
停用抑酸药可能会引起几周的额外烧心。这使停药过程不太舒服，但并不意味着人们无法停药。指南解释了如何逐步减少或停用这些药物，许多人都能做到。不过，患有某些疾病的人需要继续服用。
与该说法相关的研究
支持该说法的研究 (0)
该组中没有研究。
与该说法相矛盾或限制该说法的研究 (4)
-
Canadian guideline for stopping PPIs
Farrell B et al.. Can Fam Physician 2017 · PMID 28500192指南 / 立场声明独立交叉核查已核查摘要PPIs can be reduced or stopped in many patients, but not in Barrett's, severe oesophagitis or after bleeding ulcers.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Deprescribing.
- 研究是如何开展的？
GRADE guideline.
- 实际发现了什么？
Deprescribe eligible patients.
- 研究结果对日常生活意味着什么？
Stopping is possible.
- 该研究有哪些局限？
Abstract only.
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'cannot stop' and universal ban.
- 研究结果是否适用于德国和欧洲？
Applicable.
-
How to stop PPIs safely (AGA 2022)
Targownik LE et al.. Gastroenterology 2022 · PMID 35183361 · DOI 10.1053/j.gastro.2021.12.247指南 / 立场声明独立交叉核查已核查摘要★ 关键研究Stop PPIs without a definite indication; keep them in Barrett's, severe oesophagitis and high bleeding risk; expect temporary rebound.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
De-prescribing guidance.
- 研究是如何开展的？
Expert review.
- 实际发现了什么？
10 statements.
- 研究结果对日常生活意味着什么？
Many people can stop; some must not.
- 该研究有哪些局限？
Expert opinion.
- 它对 Elawady 的具体说法说明了什么？
Supports overuse claim; contradicts universal ban and 'cannot stop'.
- 研究结果是否适用于德国和欧洲？
Applicable.
-
Rebound symptoms after stopping PPIs – review
Lødrup AB et al.. Scand J Gastroenterol 2013 · PMID 23311977 · DOI 10.3109/00365521.2012.746395系统综述独立交叉核查已核查摘要★ 关键研究Volunteers often get mild symptoms for up to 4 weeks; patients' studies show no clear rebound.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
RAHS symptoms.
- 研究是如何开展的？
Systematic review.
- 研究了多少人、动物或样本？
5 studies.
- 实际发现了什么？
Mild transient symptoms in volunteers.
- 观察到的效应有多大？
44%.
- 研究结果对日常生活意味着什么？
Temporary symptoms.
- 该研究有哪些局限？
Few studies.
- 它对 Elawady 的具体说法说明了什么？
Supports rebound, limits 'addiction'.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Effect in patients.
-
Most people could stop unnecessary acid blockers
Koggel LM et al.. United European Gastroenterol J 2026 · PMID 42894466 · DOI 10.1002/ueg2.70297随机对照试验独立交叉核查已核查全文★ 关键研究Among outpatients without a reason for long-term PPIs, 86% using an app and 64% using a leaflet had stopped after 2 months.
64-86% stopped PPIs within 2 months
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Help people stop unneeded PPIs.
- 研究是如何开展的？
Randomised trial, app vs brochure.
- 研究了多少人、动物或样本？
163 Dutch outpatients.
- 实际发现了什么？
86% vs 64% stopped; few side effects.
- 观察到的效应有多大？
RR 1.34 (1.11-1.61).
- 研究结果对日常生活意味着什么？
Stopping is usually possible with good information.
- 该研究有哪些局限？
Short follow-up; self-report.
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'cannot stop'.
- 研究结果是否适用于德国和欧洲？
Directly applicable.
- 从该研究中明确不能得出什么结论？
Cannot tell how many restart later.
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (4)
-
Stopping a PPI can cause rebound heartburn
Reimer C et al.. Gastroenterology 2009 · PMID 19362552 · DOI 10.1053/j.gastro.2009.03.058随机对照试验被 Tayebat 档案网站引用已核查摘要★ 关键研究After stopping esomeprazole, 44% of healthy volunteers had acid symptoms vs 15% on placebo.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Rebound symptoms after PPI.
- 研究是如何开展的？
Double-blind RCT.
- 研究了多少人、动物或样本？
120 healthy adults.
- 实际发现了什么？
More acid symptoms after withdrawal.
- 观察到的效应有多大？
44% vs 15%.
- 研究结果对日常生活意味着什么？
Expect temporary symptoms when stopping.
- 该研究有哪些局限？
Short follow-up; mild symptoms.
- 它对 Elawady 的具体说法说明了什么？
Supports rebound, not 'addiction'.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Lifelong dependence.
-
Cutting down acid blockers: fewer pills, more symptoms for some
Boghossian TA et al.. Cochrane Database Syst Rev 2017 · PMID 28301676 · DOI 10.1002/14651858.CD011969.pub2系统综述独立交叉核查已核查摘要★ 关键研究In six trials of people with mild reflux, switching to as-needed PPI cut pill use by about 4 pills a week but more people had uncontrolled symptoms.
Deprescribing reduces pill burden but increases symptoms in some
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Assess stopping or reducing long-term PPIs.
- 研究是如何开展的？
Cochrane review of RCTs.
- 研究了多少人、动物或样本？
6 trials, 1758 adults.
- 实际发现了什么？
Fewer pills; more symptom relapse with on-demand use.
- 观察到的效应有多大？
RR 1.71 lack of symptom control.
- 研究结果对日常生活意味着什么？
Many can reduce PPIs; some will have more symptoms.
- 该研究有哪些局限？
Low-quality evidence; mild GERD only.
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'cannot stop', but shows stopping is not always easy.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot tell long-term effects.
-
Stopping an acid blocker caused short-lived indigestion in healthy people
Niklasson A et al.. Am J Gastroenterol 2010 · PMID 20332770 · DOI 10.1038/ajg.2010.81随机对照试验独立交叉核查已核查摘要★ 关键研究After 4 weeks of pantoprazole, 44% of healthy volunteers developed indigestion when they stopped, compared with 9% after placebo; it faded within 3 weeks.
Rebound real but resolved within 3 weeks
该研究是否支持这一具体说法？ 是 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test for rebound after stopping a PPI.
- 研究是如何开展的？
Double-blind RCT.
- 研究了多少人、动物或样本？
48 healthy volunteers.
- 实际发现了什么？
44% vs 9% developed indigestion; gone by week 3.
- 观察到的效应有多大？
RR about 5; NNH about 3.
- 研究结果对日常生活意味着什么？
Expect a few weeks of symptoms after stopping; it does not mean you need the drug.
- 该研究有哪些局限？
Small; short treatment.
- 它对 Elawady 的具体说法说明了什么？
Supports rebound claim; limits 'dependence' claim.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot show permanent dependence.
-
Are acid blockers addictive?
Namikawa K et al.. Int J Mol Sci 2024 · PMID 38791497 · DOI 10.3390/ijms25105459叙述性综述独立交叉核查已核查摘要Stopping PPIs can cause a temporary acid surge that people mistake for their old illness; warning patients helps them stop.
Rebound can lead to unnecessary restarts; preventable by informing patients
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Review rebound after PPI withdrawal.
- 研究是如何开展的？
Narrative review.
- 研究了多少人、动物或样本？
Published studies.
- 实际发现了什么？
Rebound is well established; may cause unnecessary restarts.
- 观察到的效应有多大？
40-50% symptomatic in volunteers.
- 研究结果对日常生活意味着什么？
Knowing about rebound makes stopping easier.
- 该研究有哪些局限？
Not systematic.
- 它对 Elawady 的具体说法说明了什么？
Partly supports the 'trap' idea but not 'cannot stop'.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot quantify long-term dependence.
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.
埃及
Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.
在我的国家适用什么？
一般科学评估
基本错误 言过其实：反跳是暂时的，当不再有适应证时，PPI 通常可以减量或停用。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline.. Farrell B et al.. Can Fam Physician 2017 · PMID 28500192
- AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.. Targownik LE et al.. Gastroenterology 2022 · PMID 35183361 · DOI 10.1053/j.gastro.2021.12.247
- Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment.. Lødrup AB et al.. Scand J Gastroenterol 2013 · PMID 23311977 · DOI 10.3109/00365521.2012.746395
- An App-Based Proton Pump Inhibitor Discontinuation Tool: A Multicentre, Open-Label, Randomised Superiority Trial.. Koggel LM et al.. United European Gastroenterol J 2026 · PMID 42894466 · DOI 10.1002/ueg2.70297
- Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy.. Reimer C et al.. Gastroenterology 2009 · PMID 19362552 · DOI 10.1053/j.gastro.2009.03.058
- Deprescribing versus continuation of chronic proton pump inhibitor use in adults.. Boghossian TA et al.. Cochrane Database Syst Rev 2017 · PMID 28301676 · DOI 10.1002/14651858.CD011969.pub2
- Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial.. Niklasson A et al.. Am J Gastroenterol 2010 · PMID 20332770 · DOI 10.1038/ajg.2010.81
- Rebound Acid Hypersecretion after Withdrawal of Long-Term Proton Pump Inhibitor (PPI) Treatment-Are PPIs Addictive?. Namikawa K et al.. Int J Mol Sci 2024 · PMID 38791497 · DOI 10.3390/ijms25105459